Clinical Trials Logo

Clinical Trial Summary

This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: - To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2). - To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2). - To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2). - To evaluate the maintenance of disease control after withdrawal of upadacitinib.


Clinical Trial Description

Study 1 (bDMARD-IR AS) is comprised of a 14-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 90-week open-label, long-term extension period (the Open-Label Extension Period); and a 30-day Follow-Up Visit (F/U Visit). Study 2 (nr-axSpA) is comprised of a 52-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 52-week open-label, long-term extension period (the Open-Label Extension Period); and a 30-day F/U Visit. In the Double-Blind Period for both studies, participants are randomized in a 1:1 ratio to receive either upadacitinib or placebo once daily (QD). Participants in the placebo group switch to upadacitinib 15 mg QD at Week 14 in the Open-Label Extension Period for Study 1 (bDMARD-IR AS) and Week 52 in the Open-Label Extension Period for Study 2 (nr-axSpA). Participants in remission at Week 104 have the option to enroll in a remission-withdrawal period. Study M19-944 protocol uses a common screening platform for determining eligibility into Study 1 and Study 2. Each study has its own objectives, hypothesis testing, randomization, data collection, and adequate power for primary and secondary endpoints. Analysis and reporting are conducted separately and independently for each study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04169373
Study type Interventional
Source AbbVie
Contact
Status Active, not recruiting
Phase Phase 3
Start date November 26, 2019
Completion date May 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT03564743 - Description of Spondylarthritis and Validation of ASAS Criteria in West Indian Patients Seen in Consultation of Rheumatology.
Completed NCT01219257 - Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy
Recruiting NCT05433168 - Study Evaluating the Effectiveness of Shiatsu on Fatigue in Patients With Axial Spondyloarthritis N/A
Terminated NCT03232580 - 99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis Phase 2
Recruiting NCT05039216 - Biobank for Inflammatory Chronic Diseases and Osteoporosis
Completed NCT04483648 - Cervical Stabilization Exercises in Patients With Spondyloarthritis N/A
Recruiting NCT04602091 - Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)
Not yet recruiting NCT04077957 - Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs Phase 4
Recruiting NCT05290363 - The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis N/A
Not yet recruiting NCT05006690 - Telerehabilitation, Face-to-Face and Home-Based Spinal Stabilization Exercise Training in Patients With Spondyloarthritis N/A
Completed NCT02998398 - Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital
Completed NCT02148640 - The NOR-SWITCH Study Phase 4
Completed NCT01174186 - Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Phase 4
Recruiting NCT04499001 - Effect of Pharmaceutical Consultations Just Before Rheumatology Consultations on Improving Knowledge and Skills for Patients With Inflammatory Arthritis With Subcutaneous Biologic DMARDs
Completed NCT03253796 - Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038) Phase 4
Recruiting NCT04292067 - Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis
Completed NCT04946539 - Value of Ultrasonographic Enthesitis Assessment in Spondyloarthritis
Recruiting NCT03983473 - Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease. N/A
Terminated NCT03345355 - MRI of Sacroiliac Joints: Evaluation of Accuracy of Dixon Sequences in the Diagnosis of Axial Spondyloarthritis
Completed NCT04360785 - Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis N/A